

Date: May 14, 2024

To,

- 1) BSE Limited (Scrip Code: 500124) Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai- 400001
- 2) National Stock Exchange of India Limited (Scrip Code: DRREDDY)
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Mumbai - 400 051
- 3) NSE IFSC Limited
Unit No. 1201, Brigade International Financial Centre,
12th floor, Block-14, Road 1C, Zone-1, Gift SEZ,
Gift City, Gandhinagar, Gujarat – 382355, India
- 4) New York Stock Exchange Inc. (NYSE)
11, Wall Street, New York, 10005, USA
- 5) The Company Secretary,
Dr. Reddy's Laboratories Limited
8-2-337, Road No-3, Banjara Hills, Hyderabad-
500034, Telangana, India.

Sub: Prior intimation under Regulation 10(5) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for proposed acquisition of shares

Dear Sir/ Ma'am,

In compliance of Regulation 10(5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, the undersigned being part of the Promoter and Promoter Group of the Dr. Reddy's Laboratories Limited ('Target Company'/'TC'), hereby furnish the **prior intimation** in the specified format under the said Regulation 10(5) in respect of proposed *inter-se transfer* of 3,43,45,308 (20.59%) shares of the Target Company through an off- market transfer without consideration in the following manner:

1. *Inter-se* transfer (by way of distribution) of 1,51,26,124 (9.07%) shares from APS Trust to Mr. K Satish Reddy, being the beneficiary of the Trust, i.e. amongst the promoters and promoter group.
2. *Inter-se* transfer (by way of distribution) of 1,92,19,184 (11.52%) shares from APS Trust to Mr. Gunupati Venkateswara Prasad, being the beneficiary of the Trust, i.e. amongst the promoters and promoter group.

The transfer between the APS Trust to Mr. K Satish Reddy and Mr. Gunupati Venkateswara Prasad is in terms of exemption provided in Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Further, there will be no change in the total shareholding of the Promoters and Promoter Group after such *inter-se* transfer of shares of TC.

Thanking You.

(Mr. K Satish Reddy)

**Promoter of
Reddy's**

**Dr. Reddy's
Laboratories Limited**

(Mr. G V Prasad)

**Laboratories Promoter of
Limited (Acquirer) (Acquirer)**

Dr.

Encl: as above

Disclosures under Regulation 10(5) – Intimation to Stock Exchanges in respect of acquisition under Regulation 10(1)(a) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

1	Name of the Target Company (TC)	Dr. Reddy's Laboratories Limited
2	Name of the acquirer(s)	Mr. K Satish Reddy Mr. G V Prasad
3	Whether the acquirer(s) is/ are promoters of the TC prior to the transaction. If not, nature of relationship or association with the TC or its promoters	Yes, Mr. K Satish Reddy and Mr. G V Prasad are promoters of TC and are disclosed as Promoters in the shareholding pattern filed by TC.
4	Details of the proposed acquisition	
	a Name of the person(s) from whom shares are to be acquired	APS Trust - disclosed as promoters of TC in the shareholding pattern filed by TC.
	b Proposed date of acquisition	On or after May 22, 2024
	c Number of shares to be acquired from each person mentioned in 4(a) above	3,43,45,308 shares held by APS Trust in the TC will be distributed as follows: Mr. K Satish Reddy - 1,51,26,124 shares. Mr. G V Prasad – 1,92,19,184 shares
	d Total shares to be acquired as % of share capital of TC	Acquirers in aggregate will acquire 20.59% of the shares held by APS Trust in TC pursuant to distribution to beneficiaries, in the following manner: Mr. K. Satish Reddy - 9.07%. Mr. G. V. Prasad - 11.52%
	e Price at which shares are proposed to be acquired	NIL. Shares are proposed to be transferred by way of distribution of corpus from APS Trust to the beneficiaries. Therefore, no consideration is involved.
	f Rationale, if any, for the proposed transfer	The proposed acquisition is a transfer to facilitate for smooth succession and to streamline the family's assets and businesses.
5	Relevant sub-clause of regulation 10(1)(a) under which the acquirer is exempted from making open offer	Regulation 10(1)(a)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

6	If, frequently traded, volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice as traded on the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period.	<p>The Shares are proposed to be transferred by way of distribution of corpus from APS Trust to its beneficiaries, thus no consideration is involved in such transfer.</p> <p>The shares of the Target Company are frequently traded in terms of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The volume weighted average market price for a period of 60 trading days preceding the date of issuance of this notice i.e., May 14, 2024, as traded on the stock exchange where the maximum volume of trading in the shares of the TC are recorded during such period i.e., NSE is INR 6213.84.</p>
---	--	---

7	If in-frequently traded, the price as determined in terms of clause (e) of sub-regulation (2) of regulation 8.	Not Applicable.				
8	Declaration by the acquirer, that the acquisition price would not be higher by more than 25% of the price computed in point 6 or point 7 as applicable.	No consideration is involved.				
9	<p>(i) Declaration by the acquirer, that the transferor and transferee have complied (during 3 years prior to the date of proposed acquisition)/ will comply with applicable disclosure requirements in Chapter V of the Takeover Regulations, 2011 (corresponding provisions of the repealed Takeover Regulations 1997)</p> <p>(ii) The aforesaid disclosures made during previous 3 years prior to the date of proposed acquisition to be furnished.</p>	Enclosed as "Annexure A"				
10	Declaration by the acquirer that all the conditions specified under regulation 10(1)(a) with respect to exemptions has been duly complied with.	Enclosed as "Annexure A"				
11	Shareholding details	Before the proposed transaction		After the proposed transaction		
		No. of shares/ voting rights	% w.r.t total share capital of TC	No. of shares/ voting rights	% w.r.t total share capital of TC	
	a	Acquirer(s) and PACs (other than sellers) (*)				
		Acquirer(s)				
		(i) K Satish Reddy	9,01,002	0.54	1,60,27,126	9.61
	(ii) G V Prasad	0	0.00	1,92,19,184	11.52	

Person acting in concert (other than sellers)					
(i)	Gunupati Venkateswara Prasad HUF	25,43,418	1.52	25,43,418	1.52
(ii)	Anuradha Gunupati	9,205	0.01	9,205	0.01
(iii)	Samrajyam Reddy Kallam	11,20,499	0.67	11,20,499	0.67
(iv)	Kallam Satish Reddy HUF	55,23,677	3.31	55,23,677	3.31
(v)	Sharathchandra Reddy Gunupati	2,600	0.00	2,600	0.00
(vi)	Deepti Reddy Kallam	5,140	0.00	5,140	0.00
(vii)	G Vani Sanjana Reddy	5,140	0.00	5,140	0.00
(viii)	Gunupati Mallika Reddy	5,139	0.00	5,139	0.00
(ix)	K Shravya Reddy	0	0.00	0	0.00
(x)	K Vishal Reddy	0	0.00	0	0.00
(xi)	VSD Holdings & Advisory LLP	0	0.00	0	0.00
Total Acquirer(s) and PACs (other than sellers) (*)		1,01,15,820	6.06	4,44,61,128	26.65
b	Seller(s): APS Trust	3,43,45,308	20.59	0	0.00
Total Sellers		3,43,45,308	20.59	0	0.00
Total (a+b)		4,44,61,128	26.65	4,44,61,128	26.65

Note:

- (*) Shareholding of each entity may be shown separately and then collectively in a group.
- The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

(Mr. K Satish Reddy)
(Acquirer)

Date: May 14, 2024 Place: Hyderabad
(Mr. G V Prasad)
(Acquirer)

DECLARATION BY ACQUIRERS

This is with respect to the following proposed acquisition of shares by *inter-se*, within the Promoters and Promoter Group of **Dr. Reddy's Labs** in the following manner:

- (i) *Inter-se* Transfer (by way of distribution of corpus to its beneficiaries) of shares from APS Trust to Mr. K Satish Reddy.
- (ii) *Inter-se* Transfer (by way of distribution of corpus to its beneficiaries) of shares from APS Trust to Mr. G V Prasad.

In this regard, the undersigned being the proposed acquirer to the proposed acquisition, hereby declares that:

- a. the transferor and transferee have complied with applicable disclosures of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (applicable disclosures under Chapter V, made during previous 3 years (2023-24, as well as till date for 2024-25) prior to the proposed acquisition) as set out in Annexure.
- b. the transferor and transferee will comply with applicable disclosures under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
- c. all the conditions specified under Regulation 10(1)(a) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 with respect to exemption from disclosure are satisfied.

(Mr. K Satish Reddy) (Acquirer)

Date: May 14, 2024 Place: Hyderabad **(Mr. G V Prasad)**
(Acquirer)

ANNEXURES

Date: 07/04/2021

The Secretary / Executive Director
BSE Ltd
National Stock Exchange of India Limited

Dear Sir/Madam,

Ref: Dr. Reddy's Laboratories Limited
Stock Code: BSE – 500124
NSE – DRREDDY-EQ

Sub: Disclosures under Regulations 30(3) and 31(5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

With reference to the above, we are enclosing a statement showing the aggregate shareholding of the promoter group / persons acting in concert along with the copies of disclosures under Regulations 30(1), 30(2) and 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011, received from the respective individual/entities.

With regards,




Satish Reddy

Enc: as above

CC: 1. Dr. Reddy's Laboratories Limited
2. New York Stock Exchange, Inc.
3. NSE IFSC Ltd.

Statement showing the shareholding of Promoter Group and Persons Acting in Concert

Sr. No.	Name of the Promoters and persons acting in concert	Number of shares held as on 31.03.2021	% w.r.t. total share /voting capital	% of total diluted share/voting capital of TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC
1.	G. V. Prasad	Nil	Nil	Nil
2.	Kallam Satish Reddy	898,432	0.54	0.54
3.	Kallam Samrajyam	1,115,360	0.67	0.67
4.	G. Anuradha	1,496	0.00	0.00
5.	Dr. Reddy's Holdings Limited	41,325,300	24.85	24.85
6.	K. Deepti Reddy	Nil	Nil	Nil
7.	APS Trust	Nil	Nil	Nil
8.	VSD Holdings & Advisory LLP	Nil	Nil	Nil
9.	K. Satish Reddy (HUF)	Nil	Nil	Nil
10.	G. Vani Sanjana Reddy	Nil	Nil	Nil
11.	G. Mallika Reddy	Nil	Nil	Nil
12.	G. V. Prasad (HUF)	1,117,940	0.67	0.67
13.	G Sharathchandra Reddy	2,600	0.00	0.00
14.	K Shravya Reddy	Nil	Nil	Nil
15.	K Vishal Reddy	Nil	Nil	Nil
	Total	4,44,61,128	26.74	26.74


Satish Reddy

Place: Hyderabad

Date: 07/04/2021

ANNEXURE – 1

Format for Disclosures under Regulation 30(1), 30(2) and 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A-Details of Shareholding

1. Name of the Target Company (TC)	Dr. Reddy's Laboratories Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	1. BSE Ltd. 2. National Stock Exchange of India Limited, 3. New York Stock Exchange Inc. 4. NSE IFSC Ltd.		
3. Particulars of the shareholder: a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	NA Mr. G V Prasad		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31, 2021, holding of:			
a) Shares	Nil	Nil	Nil
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	Nil	Nil	Nil

Encumbrance (directly or indirectly) on shares – Not Applicable.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Place: Hyderabad
Date: 06/04/2021


 G V Prasad

ANNEXURE – 1


Format for Disclosures under Regulation 30(1), 30(2) and 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A-Details of Shareholding

1. Name of the Target Company (TC)	Dr. Reddy's Laboratories Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	1. BSE Ltd. 2. National Stock Exchange of India Limited. 3. New York Stock Exchange Inc. 4. NSE IFSC Ltd.		
3. Particulars of the shareholder: a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	NA Mrs. G Anuradha		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31, 2021, holding of:			
a) Shares	1,496	0.00	0.00
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	1,496	0.00	0.00

There is no encumbrance (directly or indirectly) on these shares.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

* 
G Anuradha

Place: Hyderabad
Date: 08/04/2021

ANNEXURE – 1

Format for Disclosures under Regulation 30(1), 30(2) and 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A-Details of Shareholding

1. Name of the Target Company (TC)	Dr. Reddy's Laboratories Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	1. BSE Ltd. 2. National Stock Exchange of India Limited. 3. New York Stock Exchange Inc. 4. NSE IFSC Ltd.		
3. Particulars of the shareholder: a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	NA Mrs. K Deepti Reddy		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31, 2021, holding of:			
a) Shares	Nil	Nil	Nil
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	Nil	Nil	Nil

Encumbrance (directly or indirectly) on shares – Not applicable

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Deepti Reddy

K Deepti Reddy

Place: *Hyderabad*
Date: *01/04/2021*

ANNEXURE – 1

Format for Disclosures under Regulation 30(1), 30(2) and 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011


Part-A-Details of Shareholding

1. Name of the Target Company (TC)	Dr. Reddy's Laboratories Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	1. BSE Ltd. 2. National Stock Exchange of India Limited. 3. New York Stock Exchange Inc. 4. NSE IFSC Ltd.		
3. Particulars of the shareholder: a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	NA APS Trust		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31, 2021, holding of:			
a) Shares	Nil	Nil	Nil
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	Nil	Nil	Nil

Encumbrance (directly or indirectly) on shares – Not applicable.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

For APS Trust


Authorised Signatory

Place: Hyderabad

Date: 01/04/2021

ANNEXURE – 1

Format for Disclosures under Regulation 30(1), 30(2) and 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A-Details of Shareholding

1. Name of the Target Company (TC)	Dr. Reddy's Laboratories Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	1. BSE Ltd. 2. National Stock Exchange of India Limited. 3. New York Stock Exchange Inc. 4. NSE IFSC Ltd.		
3. Particulars of the shareholder: a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	NA K Satish Reddy (HUF)		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31, 2021, holding of:			
a) Shares	Nil	Nil	Nil
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	Nil	Nil	Nil

Encumbrance (directly or indirectly) on shares – Not applicable

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.



K Satish Reddy HUF
Karta

Place: Hyderabad

Date: 01/04/2021

ANNEXURE – 1

Format for Disclosures under Regulation 30(1), 30(2) and 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A-Details of Shareholding

1. Name of the Target Company (TC)	Dr. Reddy's Laboratories Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	1. BSE Ltd. 2. National Stock Exchange of India Limited. 3. New York Stock Exchange Inc. 4. NSE IFSC Ltd.		
3. Particulars of the shareholder: a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	NA Ms. G Mallika Reddy		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31, 2021, holding of:			
a) Shares	Nil	Nil	Nil
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	Nil	Nil	Nil

Encumbrance (directly or indirectly) on shares – Not applicable.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Place: Hyderabad
Date: 06/04/2021

+ 
G Mallika Reddy

ANNEXURE – 1

Format for Disclosures under Regulation 30(1), 30(2) and 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A-Details of Shareholding

1. Name of the Target Company (TC)	Dr. Reddy's Laboratories Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	1. BSE Ltd. 2. National Stock Exchange of India Limited. 3. New York Stock Exchange Inc. 4. NSE IFSC Ltd.		
3. Particulars of the shareholder: a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	NA G V Prasad (HUF)		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31, 2021, holding of:			
a) Shares	1,117,940	0.67	0.67
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.	-	-	-
Total	1,117,940	0.67	0.67

There is no encumbrance (directly or indirectly) on these shares.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

*



G V Prasad HUF
Karta

Place: Hyderabad

Date: 06/04/2021

ANNEXURE – 1

Format for Disclosures under Regulation 30(1), 30(2) and 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A-Details of Shareholding

1. Name of the Target Company (TC)	Dr. Reddy's Laboratories Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	1. BSE Ltd. 2. National Stock Exchange of India Limited. 3. New York Stock Exchange Inc. 4. NSE IFSC Ltd.		
3. Particulars of the shareholder: a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	NA Mr. G Sharathchandra Reddy		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31, 2021, holding of:			
a) Shares	2,600	0.00	0.00
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	2,600	0.00	0.00

There are no encumbrance (directly or indirectly) on these shares.

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

GUNUPATI
✗ SHARATHCHANDR
A REDDY

Digitally signed by GUNUPATI SHARATHCHANDRA REDDY
DN: c=IN, o=Person, 2.5.4.30=sharathchandra@reddy.com, email=sharathchandra@reddy.com, ou=TELANGANA, cn=GUNUPATI SHARATHCHANDRA REDDY
Date: 2021.04.06 16:40:28 +05'30'

G Sharathchandra Reddy

Place: Hyderabad
Date: 06-04-2021

ANNEXURE – 1

Format for Disclosures under Regulation 30(1), 30(2) and 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011

Part-A-Details of Shareholding

1. Name of the Target Company (TC)	Dr. Reddy's Laboratories Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	1. BSE Ltd. 2. National Stock Exchange of India Limited. 3. New York Stock Exchange Inc. 4. NSE IFSC Ltd.		
3. Particulars of the shareholder: a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	NA Ms. K Shravya Reddy		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31, 2021, holding of:			
a) Shares	Nil	Nil	Nil
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	Nil	Nil	Nil

Encumbrance (directly or indirectly) on shares – Not applicable

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.



K Shravya Reddy

Place: Hyderabad
Date: 01/04/2021

ANNEXURE – 1

Format for Disclosures under Regulation 30(1), 30(2) and 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011


Part-A-Details of Shareholding

1. Name of the Target Company (TC)	Dr. Reddy's Laboratories Limited		
2. Name(s) of the Stock Exchange(s) where the shares of the TC are listed	1. BSE Ltd. 2. National Stock Exchange of India Limited. 3. New York Stock Exchange Inc. 4. NSE IFSC Ltd.		
3. Particulars of the shareholder: a. Name of person(s) together with Person Acting in Concert (PAC) whose total holding (including that in the form of shares, warrants, convertible securities and any other instrument that would entitle the holder to receive shares in the TC) is more than 25% of the voting rights of the TC. or b. Name(s) of promoter(s), member of the promoter group and PAC with him.	NA K Vishal Reddy		
4. Particulars of the shareholding of person(s) mentioned at (3) above	Number of shares	% w. r. t. total share /voting capital wherever applicable	% of total diluted share/voting capital of TC (*)
As on March 31, 2021, holding of:			
a) Shares	Nil	Nil	Nil
b) Voting Rights (otherwise than by shares)	-	-	-
c) Warrants,	-	-	-
d) Convertible Securities	-	-	-
e) Any other instrument that would entitle the holder to receive shares in the TC.			
Total	Nil	Nil	Nil

Encumbrance (directly or indirectly) on shares – Not Applicable

(*) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Place: Hyderabad
Date: 01/04/2021


K Vishal Reddy

Date: April 5, 2022

To,
BSE Ltd
National Stock Exchange of India Limited

Dear Sir/Madam,

Ref: **Dr. Reddy's Laboratories Limited**
Stock Code: BSE – 500124
NSE – DRREDDY-EQ

Sub: **Disclosures under Regulation 31(5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011**

Pursuant to Regulation 31(4) and (5) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, we hereby declare that the Promoters or Promoter Group & Persons Acting in Concert of Dr. Reddy's Laboratories Limited, (the Company) have not created any encumbrance on the shares of the Company, directly or indirectly, during the financial year 2021-22.

This is for your information and records.

Thanking you,
Yours faithfully,



Satish Reddy

For & on behalf of

*Promoter/Promoter group/Persons Acting in Concert of
Dr. Reddy's Laboratories Limited*



G V Prasad

CC: 1. Dr. Reddy's Laboratories Limited
2. New York Stock Exchange, Inc.
3. NSE IFSC Ltd.

Name of the Promoters/Promoter Group or Persons Acting in Concert

- | | |
|---------------------------------|--------------------------------|
| 1. G. V. Prasad | 2. Kallam Satish Reddy |
| 3. Kallam Samrajyam | 4. G. Anuradha |
| 5. Dr. Reddy's Holdings Limited | 6. K. Deepti Reddy |
| 7. APS Trust | 8. VSD Holdings & Advisory LLP |
| 9. K. Satish Reddy (HUF) | 10. G. Vani Sanjana Reddy |
| 11. G. Mallika Reddy | 12. G. V. Prasad (HUF) |
| 13. G Sharathchandra Reddy | 14. K Shravya Reddy |
| 15. K Vishal Reddy | |

April 25, 2022

To, BSE Limited, Corporate Relationship Department, 25 th Floor, P J Towers, Dalal Street, Fort, Mumbai – 400001 Security Code: 500124	To, National Stock Exchange of India Ltd, Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 Security Code: DRREDDY-EQ
--	---

Dear Sir/Madam,

Sub: Disclosure under Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011

Ref: Scheme of Amalgamation and Arrangement between Dr. Reddy's Holdings Limited ("DRHL" or "Amalgamating Company") and Dr. Reddy's Laboratories Limited ("DRL" or "Amalgamated Company") and their respective shareholders ("Scheme")

Pursuant to Regulation 10(6) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (hereinafter referred to as 'SAST Regulations') we wish to inform you that, we, in our capacity as the shareholders of DRHL, have acquired the equity shares of Dr. Reddy's Laboratories Limited, a listed company, pursuant to the Scheme.

In this connection please find enclosed the disclosure as per Regulation 10(6) of the SAST Regulations.

We request you to kindly take this intimation on record.

Thanking you.

Yours Faithfully,


G V Prasad
(For and on behalf all the acquirers)

Date: April 25, 2022

Place: Hyderabad

CC: 1. New York Stock Exchange, INC.
2. NSE IFSC Ltd.

Disclosures under Regulation 10(6) - Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI SAST Regulations

1.	Name of Target Company	Dr. Reddy's Laboratories Limited
2.	Name of the Acquirers	<ol style="list-style-type: none"> 1. Mrs. Anuradha Gunupati 2. Mrs. Samrajyam Reddy Kallam 3. Mr. Satish Reddy Kallam 4. G.V. Prasad HUF 5. K Satish Reddy HUF 6. Ms. G V Sanjana Reddy 7. Mrs. K Deepti Reddy 8. Ms. G Mallika Reddy 9. APS Trust
3.	Name of the stock exchange where shares of the Target Company are listed	BSE Limited and National Stock Exchange of India Ltd
4.	Details of the transactions including rationale, if any, for the transfer/ acquisition of shares	<p>Acquisition of equity shares pursuant to the Scheme of Amalgamation and Arrangement between Dr. Reddy's Holdings Limited ("DRHL" or "Amalgamating Company") and Dr. Reddy's Laboratories Limited ("DRL" or "Amalgamated Company") and their respective shareholders, duly sanctioned by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("Hon'ble NCLT") by way of Order dated April 5, 2022 certified copy of which was received on April 7, 2022.</p> <p>Amalgamating Company was equity shareholder holding 4,13,25,300 (24.83%) equity shares of DRL. Pursuant to the aforesaid Scheme of Amalgamation and Arrangement, 4,13,25,300 equity shares held by the Amalgamating Company in the Amalgamated Company stand cancelled and in accordance of the aforesaid Scheme, DRL has issued and allotted same number of equity shares (i.e. 4,13,25,300) to the shareholders of DRHL in proportion to the shares held by them in DRHL. Accordingly, there is no change in the aggregate shareholding of the Promoter/ Promoter Group of the Amalgamated Company, post allotment/ cancellation of shares.</p>
5.	Relevant regulation under which the acquirer is exempted from making open offer	Regulation 10(1)(d)(ii) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
6.	Whether disclosure of proposed acquisition was required to be made under Regulation 10(5) and if so, <ul style="list-style-type: none"> - Whether disclosure was made and whether it was made within the timeline specified under the Regulations - Date of filing with the stock exchange 	Not Applicable

7.	Details of Acquisition		Disclosures required to be made under Regulation 10(5)		Whether disclosures under Regulation 10(5) are actually made	
	a.	Name of the Transferor / Seller	Not Applicable		Not Applicable	
	b.	Date of Acquisition	Not Applicable		Not Applicable	
	c.	Number of shares/voting rights in respect of the acquisitions from each person mentioned in 7(a) above	Not Applicable		Not Applicable	
	d.	Total shares proposed to be acquired/ actually acquired as a % of diluted share capital of Target Company	Not Applicable		Not Applicable	
	e.	Price at which shares proposed to be acquired/ actually acquired	Not Applicable		Not Applicable	
8.	Shareholding Details		Pre-Transaction		Post Transaction	
			No. of Shares Held	% w.r.t total share capital of TC	No. of Shares Held	% w.r.t total share capital of TC
	a.	Each Acquirer/ Transferee (*):				
		- Mrs. Anuradha Gunupati	1,496	0.00	9,205	0.01
		- Mrs. Samrajyam Reddy Kallam	11,15,360	0.67	11,20,499	0.67
		- Mr. Satish Reddy Kallam	8,98,432	0.54	9,01,002	0.54
		- G. V. Prasad HUF	11,17,940	0.67	25,43,418	1.53
		- K Satish Reddy HUF	-	-	55,23,677	3.32
		- Ms. G V Sanjana Reddy	-	-	5,140	0.00
		- Mrs. K Deepti Reddy	-	-	5,140	0.00
		- Ms. G Mallika Reddy	-	-	5,139	0.00
		- APS Trust	-	-	3,43,45,308	20.64
		- Mr. Sharathchandra Reddy Gunupati	2,600	0.00	2,600	0.00
	b.	Each Seller / Transferor	Not Applicable. Please refer comments in Point No. 4 above			



G V Prasad

(For and on behalf all the acquirers)

Date: April 25, 2022

Place: Hyderabad

April 25, 2022

To, BSE Limited, Corporate Relationship Department, 25 th Floor, P J Towers, Dalal Street, Fort, Mumbai – 400001 Scrip Code: 500124	To, National Stock Exchange of India Ltd, Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 Scrip Code: DRREDDY-EQ
---	--

Dear Sir/Madam,

Sub: Disclosure under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Ref: Scheme of Amalgamation and Arrangement between Dr. Reddy's Holdings Limited ("DRHL" or "Amalgamating Company") and Dr. Reddy's Laboratories Limited ("DRL" or "Amalgamated Company") and their respective shareholders ("Scheme")

Pursuant to Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (hereinafter referred to as 'SEBI SAST') we wish to inform you that pursuant to the Scheme, we have acquired equity shares of Dr. Reddy's Laboratories Limited.

In this connection, please find enclosed the disclosure as per Regulation 29(1) of SEBI SAST.

Request you to kindly take the same on record and oblige.

Thanking you.

Yours Faithfully,


G V Prasad
(For and on behalf all the acquirers)

Date: April 25, 2022

Place: Hyderabad

CC: 1. The Company Secretary, Dr. Reddy's Laboratories Limited.
2. New York Stock Exchange, INC.
3. NSE IFSC Ltd.

Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011

Part-A- Details of the Acquisition

Name of Target Company	Dr. Reddy's Laboratories Limited		
Name of the acquirer and Persons Acting in Concert (PAC) with the acquirer	<ol style="list-style-type: none"> 1. Mrs. Anuradha Gunupati 2. Mrs. Samrajyam Reddy Kallam 3. Mr. Satish Reddy Kallam 4. G.V. Prasad HUF 5. K Satish Reddy HUF 6. Ms. G V Sanjana Reddy 7. Mrs. K Deepti Reddy 8. Ms. G Mallika Reddy 9. APS Trust 		
Whether the acquirer belongs to Promoter/ Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t total diluted share / voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	4,44,61,128 (Details as per Annexure A)	26.72% (Details as per Annexure A)	26.72% (Details as per Annexure A)
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)			
c) Voting rights (VR) otherwise than by shares			
d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in TC (specify holding in each category)			
e) Total (a+b+c+d)	4,44,61,128 (Details as per Annexure A)	26.72% (Details as per Annexure A)	26.72% (Details as per Annexure A)
Details of acquisition / sale:			
a) Shares carrying voting rights acquired / sold	4,13,25,300 (Please refer note below and details as per Annexure A)	24.83% (Please refer note below and details as per Annexure A)	24.83% (Please refer note below and details as per Annexure A)
b) VRs acquired / sold otherwise than by shares			

c) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in TC (specify holding in each category) acquired / sold			
d) Shares encumbered / invoked/released by the acquirer			
e) Total (a+b+c+/-d)	4,13,25,300 (Please refer note below and details as per Annexure A)	24.83% (Please refer note below and details as per Annexure A)	24.83% (Please refer note below and details as per Annexure A)
After the acquisition / sale, holding of acquirer along with PACs of:			
a) Shares carrying voting rights acquired	4,44,61,128 (Details as per Annexure A)	26.72% (Details as per Annexure A)	26.72% (Details as per Annexure A)
b) Shares encumbered with the acquirer			
c) VRs otherwise than by shares			
d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
e) Total (a+b+c+d)	4,44,61,128 (Details as per Annexure A)	26.72% (Details as per Annexure A)	26.72% (Details as per Annexure A)
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Please refer note below		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc	Please refer note below		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	22 April 2022		
Equity share capital / total voting capital of the TC before the said acquisition / sale	Rs. 83,21,29,245/- divided into 16,64,25,849 Equity Shares of Rs. 5 each		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	Rs. 83,21,29,245/- divided into 16,64,25,849 Equity Shares of Rs. 5 each		
Total diluted share/voting capital of the TC after the said acquisition	Rs. 83,21,29,245/- divided into 16,64,25,849 Equity Shares of Rs. 5 each		

Note:

Dr. Reddy's Holdings Limited ("DRHL" or "Amalgamating Company") was part of the Promoter Group and was holding 4,13,25,300 equity shares in Dr. Reddy's Laboratories Limited ("DRL" or "Amalgamated Company"). Pursuant to the Scheme of Amalgamation and Arrangement for transfer and vesting of DRHL into DRL, as sanctioned by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("Hon'ble NCLT") by way of Order dated April 5, 2022 certified copy of which was

received on April 7, 2022, 4,13,25,300 equity shares held by the Amalgamating Company in the Amalgamated Company stand cancelled and in accordance of the aforesaid Scheme, DRL has issued and allotted same number of equity shares (i.e. 4,13,25,300) to the shareholders of DRHL in proportion to the shares held by them in DRHL. Accordingly, there is no change in the aggregate shareholding of the Promoter / Promoter Group of the Amalgamated Company, post allotment / cancellation of shares.



G V Prasad

(For and on behalf all the acquirers)



Date: April 25, 2022

Place: Hyderabad

Annexure A Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Details of shareholdings of Persons acting in concert

Sr. No.	Name of the Shareholder	Pre Transaction		Acquisition / (Disposal) pursuant to the Transaction		Post Transaction	
		No of shares held in TC	% w.r.t. total share capital of TC	No of shares held in TC	% w.r.t. total share capital of TC	No of shares held in TC	% w.r.t. total share capital of TC
1	Mrs. Anuradha Gunupati	1,496	0.00	7,709	0.00	9,205	0.01
2	Mrs. Samrajyam Reddy Kallam	11,15,360	0.67	5,139	0.00	11,20,499	0.67
3	Mr. Satish Reddy Kallam	8,98,432	0.54	2,570	0.00	9,01,002	0.54
4	G. V. Prasad HUF	11,17,940	0.67	14,25,478	0.86	25,43,418	1.53
5	Mr. Sharathchandra Reddy Gunupati	2,600	0.00	-	-	2,600	0.00
6	K Satish Reddy HUF	-	-	55,23,677	3.32	55,23,677	3.32
7	Ms. G V Sanjana Reddy	-	-	5,140	0.00	5,140	0.00
8	Mrs. K Deepti Reddy	-	-	5,140	0.00	5,140	0.00
9	Ms. G Mallika Reddy	-	-	5,139	0.00	5,139	0.00
10	Dr. Reddy's Holdings Ltd*	4,13,25,300	24.83	(4,13,25,300)*	(24.83)	-	-
11	APS Trust	-	-	3,43,45,308	20.64	3,43,45,308	20.64
	Total	4,44,61,128	26.72	-	-	4,44,61,128	26.72

*Pursuant to the Scheme of Amalgamation and Arrangement, merged with Dr. Reddy's Laboratories Limited.


G V Prasad
(For and on behalf all the acquirers)

Date: April 25, 2022
Place: Hyderabad

April 25, 2022

To, BSE Limited, Corporate Relationship Department, 25 th Floor, P J Towers, Dalal Street, Fort, Mumbai – 400001 Scrip Code: 500124	To, National Stock Exchange of India Ltd, Exchange Plaza, 5 th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400051 Scrip Code: DRREDDY-EQ
---	--

Dear Sir/Madam,

Sub: Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Ref: Scheme of Amalgamation and Arrangement between Dr. Reddy's Holdings Limited ("DRHL" or "Amalgamating Company") and Dr. Reddy's Laboratories Limited ("DRL" or "Amalgamated Company") and their respective shareholders ("Scheme")

Pursuant to Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (hereinafter referred to as 'SEBI SAST') we wish to inform you that pursuant to the Scheme, we, have acquired equity shares of Dr. Reddy's Laboratories Limited.

In this connection, please find enclosed the disclosure as per Regulation 29(2) of SEBI SAST.

Request you to kindly take the same on record and oblige.

Thanking you.

Yours Faithfully,


G V Prasad

(For and on behalf all the acquirers)

Date: April 25, 2022

Place: Hyderabad

CC: 1. The Company Secretary, Dr. Reddy's Laboratories Limited.
2. New York Stock Exchange, INC.
3. NSE IFSC Ltd.

Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation, 2011

Name of Target Company	Dr. Reddy's Laboratories Limited		
Name of the acquirer and Persons Acting in Concert (PAC) with the acquirer	<ol style="list-style-type: none"> 1. Mrs. Anuradha Gunupati 2. Mrs. Samrajyam Reddy K 3. Mr. K Satish Reddy 4. G.V. Prasad HUF 5. K Satish Reddy HUF 6. Ms. G V Sanjana Reddy 7. Mrs. K Deepti Reddy 8. Ms. G Mallika Reddy 9. APS Trust 		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited and National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t total diluted share /voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a) Shares carrying voting rights	4,44,61,128 (Details as per Annexure A)	26.72% (Details as per Annexure A)	26.72% (Details as per Annexure A)
b) Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)			
c) Voting rights (VR) otherwise than by shares			
d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in TC (specify holding in each category)			
e) Total (a+b+c+d)	4,44,61,128 (Details as per Annexure A)	26.72% (Details as per Annexure A)	26.72% (Details as per Annexure A)
Details of acquisition / sale:			
a) Shares carrying voting rights acquired / sold	4,13,25,300 (Please refer note below and details as per Annexure A)	24.83% (Please refer note below and details as per Annexure A)	24.83% (Please refer note below and details as per Annexure A)
b) VRs acquired / sold otherwise than by shares			
c) Warrants / convertible securities / any other instrument that entitles the acquirer			

to receive shares carrying voting rights in TC (specify holding in each category) acquired / sold			
d) Shares encumbered / invoked/released by the acquirer			
e) Total (a+b+c+/-d)	4,13,25,300 (Please refer note below and details as per Annexure A)	24.83% (Please refer note below and details as per Annexure A)	24.83% (Please refer note below and details as per Annexure A)
After the acquisition / sale, holding of acquirer along with PACs of:			
a) Shares carrying voting rights acquired	4,44,61,128 (Details as per Annexure A)	26.72% (Details as per Annexure A)	26.72% (Details as per Annexure A)
b) Shares encumbered with the acquirer			
c) VRs otherwise than by shares			
d) Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition			
e) Total (a+b+c+d)	4,44,61,128 (Details as per Annexure A)	26.72% (Details as per Annexure A)	26.72% (Details as per Annexure A)
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Please refer note below		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	22 April 2022		
Equity share capital / total voting capital of the TC before the said acquisition / sale	Rs. 83,21,29,245/- divided into 16,64,25,849 Equity Shares of Rs. 5 each		
Equity share capital/ total voting capital of the TC after the said acquisition / sale	Rs. 83,21,29,245/- divided into 16,64,25,849 Equity Shares of Rs. 5 each		
Total diluted share/voting capital of the TC after the said acquisition	Rs. 83,21,29,245/- divided into 16,64,25,849 Equity Shares of Rs. 5 each		

Note:

Dr. Reddy's Holdings Limited ("DRHL" or "Amalgamating Company") was part of the Promoter Group and was holding 4,13,25,300 equity shares in Dr. Reddy's Laboratories Limited ("DRL" or "Amalgamated Company"). Pursuant to the Scheme of Amalgamation and Arrangement for transfer and vesting of DRHL into DRL, as sanctioned by the Hon'ble National Company Law Tribunal, Hyderabad Bench ("Hon'ble NCLT") by way of Order dated April 5, 2022 certified copy of which was received on April 7, 2022, 4,13,25,300 equity shares held by the Amalgamating Company in the Amalgamated Company stand cancelled and in accordance of the aforesaid Scheme, DRL has issued and allotted same number of equity shares (i.e. 4,13,25,300) to the shareholders of DRHL in proportion

to the shares held by them in DRHL. Accordingly, there is no change in the aggregate shareholding of the Promoter / Promoter Group of the Amalgamated Company, post allotment / cancellation of shares.



G V Prasad

(For and on behalf all the acquirers)



Date: April 25, 2022

Place: Hyderabad

Note:

(*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

Annexure A Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Details of shareholdings of Persons acting in concert

Sr. No.	Name of the Shareholder	Pre Transaction		Acquisition / Disposal pursuant to the Transaction		Post Transaction	
		No of shares held in TC	% w.r.t. total share capital of TC	No of shares held in TC	% w.r.t. total share capital of TC	No of shares held in TC	% w.r.t. total share capital of TC
1	Mrs. Anuradha Gunupati	1,496	0.00	7,709	0.00	9,205	0.01
2	Mrs. Samrajyam Reddy Kallam	11,15,360	0.67	5,139	0.00	11,20,499	0.67
3	Mr. Satish Reddy Kallam	8,98,432	0.54	2,570	0.00	9,01,002	0.54
4	G. V. Prasad HUF	11,17,940	0.67	14,25,478	0.86	25,43,418	1.53
5	Mr. Sharathchandra Reddy Gunupati	2,600	0.00	-	-	2,600	0.00
6	K Satish Reddy HUF	-	-	55,23,677	3.32	55,23,677	3.32
7	Ms. G V Sanjana Reddy	-	-	5,140	0.00	5,140	0.00
8	Mrs. K Deepti Reddy	-	-	5,140	0.00	5,140	0.00
9	Ms. G Mallika Reddy	-	-	5,139	0.00	5,139	0.00
10	Dr. Reddy's Holdings Ltd*	4,13,25,300	24.83	(4,13,25,300)*	(24.83)	-	-
11	APS Trust	-	-	3,43,45,308	20.64	3,43,45,308	20.64
	Total	4,44,61,128	26.72	-	-	4,44,61,128	26.72

*Pursuant to the Scheme of Amalgamation and Arrangement, merged with Dr. Reddy's Laboratories Limited.


G V Prasad
(For and on behalf all the acquirers)

Date: April 25, 2022
Place: Hyderabad

Date: **April 07, 2023**

To,
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)

Dear Sir/Madam,

Ref: **Dr. Reddy's Laboratories Limited**
Stock Code: BSE – 500124
NSE – DRREDDY-EQ

Sub: **Disclosures under Regulation 31(5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011**

Pursuant to Regulation 31(4) and (5) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, we hereby declare that the Promoter/Promoter group & Persons Acting in Concert in Dr. Reddy's Laboratories Limited, ("the Company") have not created any encumbrance on the shares of the Company, directly or indirectly, during the financial year 2022-23.

This is for your information and records.

Thanking you,

Yours faithfully,



K Satish Reddy



G V Prasad

***For & on behalf of Promoter/Promoter group/Persons Acting in Concert
Of Dr. Reddy's Laboratories Limited***

CC: 1. Dr. Reddy's Laboratories Limited
2. New York Stock Exchange, Inc.
3. NSE IFSC Ltd.

Name of the Promoters/Promoter Group or Persons Acting in Concert

- | | |
|--------------------------------|-----------------------------|
| 1. G. V. Prasad | 2. K Satish Reddy |
| 3. Kallam Samrajyam | 4. G. Anuradha |
| 5. K. Deepti Reddy | 6. APS Trust |
| 7. VSD Holdings & Advisory LLP | 8. K Satish Reddy (HUF) |
| 9. G. Vani Sanjana Reddy | 10. G. Mallika Reddy |
| 11. G. V. Prasad (HUF) | 12. G. Sharathchandra Reddy |
| 13. K Shravya Reddy | 14. K Vishal Reddy |

Date: 08-04-2024

To,
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)

Dear Sir/Madam,

Ref: **Dr. Reddy's Laboratories Limited**
Stock Code: BSE – 500124
NSE – DRREDDY-EQ


Sub: **Disclosures under Regulation 31(5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeover) Regulations, 2011**

Pursuant to Regulation 31(4) and (5) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, we hereby declare that the Promoter/Promoter group & Persons Acting in Concert in Dr. Reddy's Laboratories Limited, ("the Company") have not created any encumbrance on the shares of the Company, directly or indirectly, during the financial year 2023-24.

This is for your information and records.

Thanking you,

Yours faithfully,



K Satish Reddy



G V Prasad

*For & on behalf of Promoter/Promoter group/Persons Acting in Concert
Of Dr. Reddy's Laboratories Limited*

CC: 1. Dr. Reddy's Laboratories Limited
2. New York Stock Exchange, Inc.
3. NSE IFSC Ltd.

Name of the Promoters/Promoter Group or Persons Acting in Concert

- | | |
|--------------------------------|-----------------------------|
| 1. G. V. Prasad | 2. K Satish Reddy |
| 3. Kallam Samrajyam | 4. G. Anuradha |
| 5. K. Deepthi Reddy | 6. APS Trust |
| 7. VSD Holdings & Advisory LLP | 8. K Satish Reddy (HUF) |
| 9. G. Vani Sanjana Reddy | 10. G. Mallika Reddy |
| 11. G. V. Prasad (HUF) | 12. G. Sharathchandra Reddy |
| 13. K Shravya Reddy | 14. K Vishal Reddy |